Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 10
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
15 to 65
Other
GMALL01
NCT00198991
2.
German Multicenter Trial for the Treatment of Newly Diagnosed T-Lymphoblastic Lymphoma in Adults
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Active
15 to 65
Other
GMALL04
NCT00199017
Last Modified:
4/28/2008
 
First Published:
5/21/2007
3.
Phase II/III Randomized Study of Therapy Optimization Comprising Induction, Consolidation, and Intensification Regimens Followed By CNS Radiotherapy and Maintenance Therapy Comprising Thioguanine and Cytarabine in Pediatric Patients With Standard-Risk or High-Risk Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
18 and under
Other
UCHM-AML-BFM-2004
UCHM-BfArM 4022064, NCT00111345, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004
Last Modified:
10/1/2008
 
First Published:
9/30/2008
4.
Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 to 85
NCI, Pharmaceutical / Industry
OHSU-4180
4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517
5.
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
CAI
NCT00126321
6.
2CDA With Rituximab in Hairy Cell Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Other
2004-0223
NCT00412594
7.
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
CST1571AU235 / Komrokji
CST1571AUS235, NCT00594555
8.
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
AGMT_MALT
EudraCT 2008-000767-41, NCT00656812
9.
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Not specified
Other
2005-0733
NCT00492050
First Published:
11/18/2005
10.
Phase I Study of Cladribine, Cytarabine, and Imatinib Mesylate in Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other, Pharmaceutical / Industry
URCC-U26403
URCC-RSRB-10427, NOVARTIS-CSTI571AUS161, NCT00258271
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute